熱門資訊> 正文

NeoGenomics实体瘤测试获得纽约州批准

2024-10-22 20:58

NeoGenomics, Inc.(NEO) 0

NeoGenomics (NASDAQ:NEO) said on Tuesday that the New York State Department of Health has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung, allowing for immediate commercial access in the state of New York.

More on NeoGenomics

NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript
NeoGenomics, Inc. 2024 Q2 - Results - Earnings Call Presentation
NeoGenomics Q2 2024 Earnings Preview
Seeking Alpha’s Quant Rating on NeoGenomics
Historical earnings data for NeoGenomics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。